tldrdailynews.com logo
Tag

Revolution Medicines

All articles tagged with #revolution medicines

Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential
business7 days ago

Rasonque poised to reshape pancreatic cancer therapy with blockbuster potential

Revolution Medicines’ pancreatic cancer drug Rasonque will list at $39,800 for a 30-day supply, a price analysts say could help it become a blockbuster; Evercore ISI raised pancreatic cancer sales forecasts to about $2.4 billion next year and up to $15.1 billion by 2034, with potential expansion to other cancers. The FDA approved the drug for patients who’ve had one systemic therapy or aren’t candidates for multiagent therapy, and a Phase 3 front-line trial is underway, signaling strong launch momentum despite the steep price.

via BioPharma Dive|
#business#drug-pricing#fda-approval
Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch
healthcare8 days ago

Rasonque Debuts in Pancreatic Cancer as Investors Eye a Historic Launch

Revolution Medicines wins FDA approval for Rasonque (daraxonrasib) in metastatic pancreatic cancer, triggering optimism of a historic oncology launch and potential multi‑billion sales, but raising questions about first‑line use, payer coverage, and how quickly patients move from expanded‑access to commercial treatment amid a $39,800 monthly price and a broad label whose criteria for multiagent therapy remain unclear.

via Fierce Pharma|
#drug-pricing#expanded-access-program#healthcare
KRAS-targeting pancreatic cancer pill approved, signaling a broader oncology breakthrough
health8 days ago

KRAS-targeting pancreatic cancer pill approved, signaling a broader oncology breakthrough

The FDA approved Revolution Medicines’ Rasonque, a daily KRAS-targeting pill for adults with metastatic pancreatic adenocarcinoma after one prior therapy or when chemotherapy isn’t feasible. In trials, median overall survival more than doubled (13.2 months vs 6.7) and death risk was reduced by about 60%, with no KRAS mutation test required. Priced at $39,800 per 30 days and backed by patient-support and expanded-access programs, the approval is viewed as a major advance and a potential platform for RAS-driven cancers, with off-label use anticipated and ongoing development of related therapies.

via Fortune|
#fda-approval#health#oncology
Nvidia Leads a Market-Moving Mix of Tech and Biotech Stocks
markets9 days ago

Nvidia Leads a Market-Moving Mix of Tech and Biotech Stocks

Nvidia rose about 4% after earnings, with its outlook signaling roughly 70% revenue growth next year, while Abercrombie jumped ~36% on upbeat Q2 results and outlook; Revolution Medicines gained after FDA approval for a daily pancreatic cancer pill, and Apple moved higher ahead of its Sept. 9 iPhone event. Meta Platforms agreed to pay up to $18 billion to settle a multi-state lawsuit, Intuit slipped on a softer revenue forecast, and Zoom fell despite solid earnings as investors digested inflation data and Nvidia’s results in a mixed market.

via Barron's|
#abercrombie-and-fitch#intuit#markets
Access race tightens as Revolution Medicines' pancreatic cancer drug nears approval
healthcare3 months ago

Access race tightens as Revolution Medicines' pancreatic cancer drug nears approval

Patients with pancreatic cancer are pursuing Revolution Medicines' experimental drug daraxonrasib through expanded-access programs as the company nears potential approval. While there is optimism the treatment could extend lives, demand is surging and production may not keep up, raising concerns about who receives the drug first and how access will be allocated.

via statnews.com|
#daraxonrasib#drug-access#expanded-access
First-in-class KRAS therapy boosts survival in metastatic pancreatic cancer
health3 months ago

First-in-class KRAS therapy boosts survival in metastatic pancreatic cancer

A new oral drug, daraxonrasib, targets the KRAS-driven mechanism in pancreatic cancer by engaging cyclophilin A to shut down KRAS signaling. In a Phase 3 trial of 500 patients with metastatic pancreatic cancer who had prior treatment, daraxonrasib nearly doubled median survival from 6.7 to 13.2 months and reduced the risk of death by about 60% versus standard chemotherapy. The most common side effects were a skin rash, stomatitis, diarrhea, nausea and vomiting, though discontinuation due to adverse effects was lower and quality of life improved. Regulatory review by the FDA and other global authorities is the immediate next step, with expedited review likely; if approved, the drug could reach clinics within months and herald a shift toward targeted, personalized therapy and potential combination approaches to prevent resistance.

via The Conversation|
#daraxonrasib#health#kras
Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data
world3 months ago

Pancreatic cancer pill daraxonrasib shows survival boost in ASCO data

ASCO data show Revolution Medicines’ oral daraxonrasib, a molecular glue that blocks RAS, delaying cancer symptoms by more than nine months and extending median survival to 13.2 months in advanced pancreatic cancer; while not curative, it improves length and quality of life versus chemotherapy, with side effects like rash and mouth sores that are usually manageable.

via Hindustan Times|
#asco#daraxonrasib#molecular-glue
Ex-Senator Ben Sasse Enters Groundbreaking Pancreatic Cancer Trial
health4 months ago

Ex-Senator Ben Sasse Enters Groundbreaking Pancreatic Cancer Trial

Former U.S. senator Ben Sasse, diagnosed with metastatic pancreatic cancer, joined Revolution Medicines’ frontline trial of daraxonrasib. Preliminary topline data show the drug can markedly extend survival versus chemotherapy in second-line use, and Sasse reports dramatic drops in the tumor marker CA 19-9 and meaningful pain relief, with frontline use potentially even more beneficial, signaling a potential major advance in pancreatic cancer care.

via statnews.com|
#clinical-trial#daraxonrasib#health
New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results
health4 months ago

New Pancreatic Cancer Drug Daraxonrasib Delivers Landmark Phase 3 Results

Revolution Medicines announced that its pancreatic cancer drug daraxonrasib met all primary and secondary endpoints in a Phase 3 trial, nearly doubling median overall survival (13.2 months vs 6.7 months) and reducing the risk of death by about 60% versus chemotherapy, prompting an FDA filing using a Commissioner’s National Priority Voucher; safety was manageable and the company is pursuing second-line use and trials in newly diagnosed patients.

via CNBC|
#daraxonrasib#health#overall-survival